Comparison between Dev Labtech Venture IPO and Infinium Pharmachem IPO.
Dev Labtech Venture IPO is a SME Fixed Price IPO proposed to list at BSE SME while Infinium Pharmachem IPO is a SME Fixed Price proposed to list at NSE SME.
| Dev Labtech Venture IPO | Infinium Pharmachem IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Fixed Price |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Beeline Capital Advisors Pvt.Ltd. | Swastika Investmart Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Sunflower Broking Pvt.Ltd. | Swastika Investmart Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Dev Labtech Venture IPO is up to ₹10.65 Cr whereas the issue size of the Infinium Pharmachem IPO is up to ₹23.99 Cr. The final issue price of Dev Labtech Venture IPO is ₹51.00 per share and of Infinium Pharmachem IPO is ₹135.00 per share.
| Dev Labtech Venture IPO | Infinium Pharmachem IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹51.00 per share | ₹135.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹13.50 per share | |
| Market Lot Size | 2000 shares | 1000 shares |
| Fresh Issue Size | 20,88,000 shares | 17,81,000 shares |
| Fresh Issue Size (Amount) | up to ₹10.65 Cr | up to ₹23.99 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 20,88,000 shares | 17,81,000 shares |
| Issue Size Total (Amount) | up to ₹10.65 Cr | up to ₹23.99 Cr |
Dev Labtech Venture IPO opens on Mar 17, 2023, while Infinium Pharmachem IPO opens on Mar 31, 2023. The closing date of Dev Labtech Venture IPO and Infinium Pharmachem IPO is Mar 21, 2023, and Apr 05, 2023, respectively.
| Dev Labtech Venture IPO | Infinium Pharmachem IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Mar 17, 2023 | Mar 31, 2023 |
| Issue Close | Mar 21, 2023 | Apr 05, 2023 |
| Basis Of Allotment (Tentative) | Mar 24, 2023 | Apr 11, 2023 |
| Initiation of Refunds (Tentative) | Mar 27, 2023 | Apr 12, 2023 |
| Credit of Share (Tentative) | Mar 28, 2023 | Apr 13, 2023 |
| Listing date (Tentative) | Mar 29, 2023 | Apr 17, 2023 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Dev Labtech Venture IPO P/E ratio is 32.9, as compared to Infinium Pharmachem IPO P/E ratio of 7.83.
| Dev Labtech Venture IPO | Infinium Pharmachem IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.66 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 68.01 | 73.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 32.9 | 7.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹42.18 Cr. | ₹93.93 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 29.68 | 43.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 0.22 | 72 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.64 | 2.91 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹0.84 | ₹54.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 22.71 | 46.61 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Dev Labtech Venture IPO Retail Individual Investors (RII) are offered 10,44,000 shares while in Infinium Pharmachem IPO retail investors are offered 10,44,000 shares. Qualified Institutional Buyers (QIB) are offered in Dev Labtech Venture IPO and in Infinium Pharmachem IPO.
| Dev Labtech Venture IPO | Infinium Pharmachem IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 1,12,000 shares | 94,000 shares |
| QIB | ||
| NII | 10,44,000 shares | 8,70,000 shares |
| RII | 10,44,000 shares | 8,70,000 shares |
| Employee | 41,000 shares | |
| Others | ||
| Total | 20,88,000 shares | 17,81,000 shares |
Dev Labtech Venture IPO subscribed 5.47x in total, whereas Infinium Pharmachem IPO subscribed 1.92x.
| Dev Labtech Venture IPO | Infinium Pharmachem IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | 2.65x | 1.94x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 8.24x | 2.00x |
| Employee (times) | 1.29x | |
| Other (times) | ||
| Total (times) | 5.47x | 1.92x |
